Work

7506 ORAL Up to 6 years follow-up of patients receiving imatinib mesylate (Glivec) to treat unresectable or metastatic gastrointestinal stromal tumors (GISTs)

Year: 2007

Type: conference-abstract

Source: European Journal of Cancer Supplements

DOI: 10.1016/s1359-6349(07)71483-0

Authors: H. Joensuu, G.D. Demetri, M.C. Heinrich, B.L. Eisenberg, J.A. Fletcher, C.L. Corless, C.D. Fletcher, C. Blanke, D. Heintz, M. von Mehren

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2000802996

Cites:

Cited by:

Related to: 10